Verasenib (Verasol)
Product detail for Verasenib, INN: verasenib. Therapeutic area: Oncology. This record shows all linked substances, markets, applications, presentations, and labeling artefacts.
Product ID
PROD-002
INN
verasenib
Therapeutic Area
Oncology
Status
Active
Owner
Sarah Chen
Created
2022-08-12
Last Updated
2023-11-30
Markets
4
Presentations
| Form | Strength | Route |
|---|---|---|
| Concentrate for solution for infusion | 10 mg/mL | Intravenous |
| Hard capsule | 100 mg/mL | Intravitreal |
| Powder for injection | 25 mg | Subcutaneous |
| Concentrate for solution for infusion | 10 mg | Topical |
Active Substances
| ID | Name | INN | CAS | Type | Status |
|---|---|---|---|---|---|
| SUB-002 | Verasenib HCl | verasenib | 20150-85-3 | biologic | Active |
| SUB-027 | Lecanemabix | lecanemabix | 63212-37-7 | small-molecule | Pending |
Applications (4)
| Application # | Market | Procedure Type | Status | Owner | Submitted |
|---|---|---|---|---|---|
| EMA-2023-0002 | European Union | Type IA Variation | Approved | James O'Brien | 2024-05-26 |
| HSA-2023-0032 | European Union | sBLA | Draft | James O'Brien | 2023-12-12 |
| EMA-2023-0062 | European Union | Label Update | Failed | Tomoko Ikeda | 2022-09-05 |
| HSA-2023-0092 | European Union | sBLA | Failed | Nadia Petrova | 2022-05-15 |